Mitsubishi Tanabe Pharma, headquartered in Osaka, has announced that it will withdraw from the development of a new coronavirus vaccine.
It has decided to withdraw due to the fact that vaccines developed by other pharmaceutical companies are already widespread and there are issues with mass production.
At Mitsubishi Tanabe Pharma, a new coronavirus vaccine jointly developed by its Canadian subsidiary Medicago with a British pharmaceutical company was approved locally, and clinical trials were underway in Japan as well.
However, it announced on the 3rd that it would withdraw from the development of vaccines and liquidate all the businesses of this subsidiary, citing that vaccines developed by other pharmaceutical companies are already in widespread use and that there are problems in creating a system for mass production. Did.
The vaccine under development was made by inserting virus genes into a fast-growing Nicotiana plant and extracting particles from leaf cells. It was said to have advantages.
Regarding the new corona vaccine that domestic pharmaceutical companies are developing, Shionogi and Daiichi Sankyo have each applied for approval from the government, and the response has been divided.